Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$49 Mln
Revenue (TTM)
$104 Mln
Net Profit (TTM)
$0 Mln
ROE
-5.5 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
0.7
Industry P/E
--
EV/EBITDA
-1.5
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-5.6
Face value
--
Shares outstanding
9,792,460
CFO
$-3,342.56 Mln
EBITDA
$-3,644.16 Mln
Net Profit
$-3,698.95 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Bluebird bio Inc (BLUE)
| -40.4 | 22.7 | 21.8 | -72.5 | -56.3 | -64.1 | -46.3 |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|---|---|---|---|---|---|---|---|
|
Bluebird bio Inc (BLUE)
| -69.5 | -80.1 | -30.7 | -64.3 | -50.7 | -11.5 | -44.1 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 | -9.7 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 | 5.9 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO... (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. Its clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts. As of May 29, 2025, bluebird bio, Inc. was taken private. Read more
President, CEO & Director
Mr. Andrew Obenshain
President, CEO & Director
Mr. Andrew Obenshain
Headquarters
Somerville, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Bluebird bio Inc (BLUE) is $4.97 (NASDAQ) as of 02-Jun-2025 09:30 EDT. Bluebird bio Inc (BLUE) has given a return of -56.26% in the last 3 years.
Since, TTM earnings of Bluebird bio Inc (BLUE) is negative, P/E ratio is not available.
The P/B ratio of Bluebird bio Inc (BLUE) is 0.73 times as on 02-Jun-2025, a 81 discount to its peers’ median range of 3.94 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-2.22
|
-16.96
|
|
2023
|
-0.06
|
0.07
|
|
2022
|
-2.21
|
3.00
|
|
2021
|
-1.29
|
1.94
|
|
2020
|
-4.64
|
2.12
|
The 52-week high and low of Bluebird bio Inc (BLUE) are Rs 28.60 and Rs 3.20 as of 03-Apr-2026.
Bluebird bio Inc (BLUE) has a market capitalisation of $ 49 Mln as on 02-Jun-2025. As per SEBI classification, it is a Small Cap company.
Before investing in Bluebird bio Inc (BLUE), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.